HOO-IMM PLUS (Anti-Hepatitis Drug)
Hepatitis B Virus(HBV) infection is a major health problem throughout the world affecting
more than 350 million people are carriers of this virus that can cause chronic
hepatitis, liver cirrhosis, and hepatocellular carcinoma.
HOO-IMM PLUS an anti-viral treatment for acute and chronic HBV infected patients
primarily focus on the viral entry inhibition also inhibit DNA Polymerase of HBV virus
in combination with other multi targets against HBV which could block re-infection and
protect hepatocyte those are healthy liver cells opening new natural therapeutic options
without any means of side effects for HBV-infected individuals.
HOO-IMM PLUS, a herbal composite formula ensures effective action on multiple
targets simultaneously anti-HBV, anti-Hepatocellular Carcinoma (HCC) and
The anti-HBV activity of HOO-IMM PLUS has been reported by many Ayush clinicians
in India and pharmacists from Africa. HOO-IMM PLUS has been extensively clinically
studied against HBV on the inhibition of HBsAg secretion PLC/PRF/5 Cells and also the
inhibition of Hepato carcinoma in the HepG2 cell line. Clinically patients receiving Hooimm
plus reported Target not detected in HBV DNA Quantitative.
The HOO-IMM PLUS constitutes a curcumin molecule that has been proven a star key
molecule in preventing hepatocellular carcinoma. Much research has been done on
curcumin suggesting that it inhibits proliferation induces apoptosis,
potentiate attenuates ROS. But the poor systemic absorption of curcumin is a major obstacle to its efficacy.
Here we have a unique extraction procedure for Curcuma longa which yields curcumin
with high degree bioavailability and along with other herbal extract formulation that
improves the gut absorption of curcumin.
Hooimm Plus prevents liver injury from viral hepatitis. HBV individuals receiving
Hooimm plus treatment having normalized liver enzyme. The treatment prognosis reports
a normal level of the routine test of Serum Alanine Aminotransferase (ALT) or serum
glutamic pyruvic transaminase (SGPT) and Aspartate Aminotransferase (AST).
AST and SGPT is a blood test that checks for liver damage. SGPT and AST levels in the blood
rise if your liver is damaged.
1. HBV Serological markers which include HBsAg & HBeAg Elisa.
2. Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase
(SGPT) & Aspartate Aminotransferase (AST) or SGOT.
3. HBV DNA Quantification-Viral Load.
Note: Quantification of HBV DNA reflects the viral load which plays a critical role in
determining the phase of infection, deciding the treatment, and determining the response
to anti-viral treatment. This test is highly recommended in Chronic HBV- World Health
HOO-IMM Plus is a novel herbal formulation for the treatment of HIV & HBV infections
marketed by HOOTONE REMEDIES. It’s a capsule formulation consists of 750 mg
extract of 10 different plant species
Each 750 mg contains:-
Muleti Ext Glycyrrhiza glabra 75 mg
Bhui Amlaki Ext Phyllanthus Niruri 75 mg
Harda Ext Terminalia Chebula 75 mg
Bhojpatra Ext Betula Utilis 75 mg
Punnaga Ext Calophyllum Inophyllum 75 mg
Haldi Ext Curcuma Longa 75 mg
Nirgundi Ext Justica Gendarussa 75 mg
Kalmegh Ext Andrographis Paniculata 75 mg
Karela Beej Ext Memordica Charantia 75 mg
Bichu Buti Ext Urtica dioica 75 mg
HOO-IMM PLUS polyherbal formulation consists of a number of active molecules of
different plant species act on multiple targets against HBV.
Glycyrrhiza Glabra :
Glycyrrhizin, a major component of a herb (licorice), has been widely used to treat
chronic hepatitis B in Japan. This substance improves liver function with occasional
complete recovery from hepatitis
Its effects on the secretion of hepatitis B surface antigen (HBsAg) were examined in
vitro. Glycyrrhizin suppressed the secretion of HBsAg and accumulated it dose-
dependently in PLC/PRF/5 cells.
Phyllanthus Niruri :
An aqueous extract of the plant Phyllanthus niruri inhibits endogenous DNA polymerase
of hepatitis B virus and binds to the surface antigen of hepatitis B virus in vitro.
Phyllanthus significantly reduced serum HBV DNA (a marker of efficacy) as well as
HBeAg (a marker of viral replication).
A potential anti-HBV new treatment agent, ellagic acid, was isolated from the medicinal plant P. niruri,
and its physicochemical properties were characterized.
Phyllanthus niruri (Bhumyamalaki) had the ability to inhibit HBV polymerase to decrease
episomal HBV DNA content by downregulating HBV messenger RNA transcription.
Terminalia Chebula :
Studied and found that 90% of Terminalia chebula ethanolic extracts inhibited on HBs
antigen-binding assay and HBV DNA polymerase inhibition assay.
In silico analysis of potent compounds from Terminalia chebula proved to be effective
against Hepatitis B virus.
In HBs antigen-binding assay, the lyophilized ethanolic extracts of Terminalia chebula
exhibited 60% of maximum inhibition whereas the aqueous extracts showed 55% of
inhibition and the control lamivudine exhibited 60% of inhibition.
Curcuma Longa :
Curcumin treatment led to time- and dose-dependent reductions in HBsAg and HBeAg
expression and significant reductions in intracellular HBV DNA replication
Andrographis Panicula :
Dehydroandrographolide and andrographolide, two natural diterpenoids isolated
from Andrographis paniculata possessed activity against HBV DNA replication
Failed HBV Treatment :
Several anti-viral those are currently available for the treatment of HBV which includes
IFN alpha, Lamuvidine, Entecavir, Telbibudine and Tenofovir.
Interferon therapy has limited efficacy, slow-acting, and frequently causes adverse effects.
Undesirable side effects of interferon treatment are found such as fever, malaise, fatigue,
depression, hair loss, neutropenia, and thrombocytopenia.
On the other hand, the side effects of Tenofovir is no less than Interferon. The common
side effects include fever, pain, diarrhea, vomiting, depressed mood, rashes, insomnia.
Moreover, the anti-viral drug and Interferon are expensive. Moreover, if the patient drops
the Tenofovir medication even for 48 hours the HBV viral load elevates to 10 3.
Why HBV treatment is highly recommended?
HBV infection leads to severe diseases, including hepatitis, liver cirrhosis and
HBV has also been suggested to be involved in the development of pancreatic
Approximately 4 crore individuals are infected with HBV and more than 1.5 lakh people
with HBV infection die every year as a result of end-stage liver disease and
hepatocellular carcinoma in India.
Most of the mortality due to Viral Hepatitis is attributed to Hepatitis B and C,
which are also known as silent killers as more than 80% of the infected aren’t
aware of their infection.
Hepatitis B and C infections can remain asymptomatic for years, even decades,
slowly damaging the liver.
Fighting hepatitis is difficult because both hepatitis B and C are chronic
infections that often remain dormant in the body for years before damaging the
liver. Liver cirrhosis and liver cancer are the common culmination of these chronic
infections. Most people infected with the virus are not aware of their
Chronic HBV infection accounts for 40-50% of hepatocellular carcinoma (HCC)
and 20-30% cases of liver cirrhosis while chronic HCV infection accounts for 12-
32% of HCC and 12-20% of liver cirrhosis in the country.